Immunogenicity of Infanrix ™ hexa administered at 3, 5 and 11 months of age
A pooled analysis of data from four vaccination studies conducted in Europe was undertaken to assess the immunogenicity of Infanrix™ hexa (DTPa–HBV–IPV/Hib, GlaxoSmithKline Biologicals) when administered in a total of 702 healthy infants at 3, 5 and 11–12 months of age. One month after dose 2, betwe...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2012-04, Vol.30 (17), p.2710-2714 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2714 |
|---|---|
| container_issue | 17 |
| container_start_page | 2710 |
| container_title | Vaccine |
| container_volume | 30 |
| creator | Van Der Meeren, Olivier Kuriyakose, Sherine Kolhe, Devayani Hardt, Karin |
| description | A pooled analysis of data from four vaccination studies conducted in Europe was undertaken to assess the immunogenicity of Infanrix™ hexa (DTPa–HBV–IPV/Hib, GlaxoSmithKline Biologicals) when administered in a total of 702 healthy infants at 3, 5 and 11–12 months of age. One month after dose 2, between 96.3% and 100% of subjects had seroprotective antibodies against diphtheria, tetanus, hepatitis B and poliovirus types 1, 2 and 3; 91.7% against Hib and ≥99.0% were seropositive for each pertussis antigen. One month after the third dose, 98.9–100% of subjects were seroprotected/seropositive for all vaccine antigens. Geometric mean antibody concentrations/titres for each vaccine antigen increased by 6.7–52.9 fold after the third vaccine dose. No serious adverse events in DTPa–HBV–IPV/Hib recipients were vaccine related. Infanrix™ hexa induces an adequate immune response after 2-dose primary plus booster doses when administered according to a 3, 5 and 11 months schedule. |
| doi_str_mv | 10.1016/j.vaccine.2012.02.024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_948912160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X12001958</els_id><sourcerecordid>948912160</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-b8ab65724b802cbf90d158be7c31f92c5f31a6e6c15ab891c5814847f21719bf3</originalsourceid><addsrcrecordid>eNqFkstuFDEQRS0EIkPgEwDvYEEPLj_6sQGhiMdIQSxCJHaW212eeOh2B7s7yuz5Ej6NL8GtGViwAKmk2px7q3SrCHkMbA0Mype79Y2x1gdccwZ8zZaSd8gK6koUXEF9l6wYL2UhgX05IQ9S2jHGlIDmPjnhXMhGcbUiHzfDMIdxi8FbP-3p6OgmOBOiv6U_v_-gV3hrqOkGH3yaMGJHzUTFC6qoCR0FoMMYpqu06MwWH5J7zvQJHx37Kbl89_bz2Yfi_NP7zdmb88LKqpyKtjZtqSou25px27qGdaDqFisrwDXcKifAlFhaUKatG7CqBlnLynGooGmdOCXPDr7Xcfw2Y5r04JPFvjcBxznpRmYVh5Jl8vk_yZxlBoWqVEbVAbVxTCmi09fRDybuM7Rwpd7pY-Z6yVyzpWTWPTmOmNsBuz-q3yFn4OkBcGbUZht90pcX2UExBpI3TGTi9YHAHNqNx6iT9Rgsdj6inXQ3-v8u8eovB9vnm1nTf8U9pt04x5AvokGnLNAXy2ssnwE8L9GoWvwCWx6xKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1011213575</pqid></control><display><type>article</type><title>Immunogenicity of Infanrix ™ hexa administered at 3, 5 and 11 months of age</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Van Der Meeren, Olivier ; Kuriyakose, Sherine ; Kolhe, Devayani ; Hardt, Karin</creator><creatorcontrib>Van Der Meeren, Olivier ; Kuriyakose, Sherine ; Kolhe, Devayani ; Hardt, Karin</creatorcontrib><description>A pooled analysis of data from four vaccination studies conducted in Europe was undertaken to assess the immunogenicity of Infanrix™ hexa (DTPa–HBV–IPV/Hib, GlaxoSmithKline Biologicals) when administered in a total of 702 healthy infants at 3, 5 and 11–12 months of age. One month after dose 2, between 96.3% and 100% of subjects had seroprotective antibodies against diphtheria, tetanus, hepatitis B and poliovirus types 1, 2 and 3; 91.7% against Hib and ≥99.0% were seropositive for each pertussis antigen. One month after the third dose, 98.9–100% of subjects were seroprotected/seropositive for all vaccine antigens. Geometric mean antibody concentrations/titres for each vaccine antigen increased by 6.7–52.9 fold after the third vaccine dose. No serious adverse events in DTPa–HBV–IPV/Hib recipients were vaccine related. Infanrix™ hexa induces an adequate immune response after 2-dose primary plus booster doses when administered according to a 3, 5 and 11 months schedule.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2012.02.024</identifier><identifier>PMID: 22349525</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject><![CDATA[Age ; Allergy and Immunology ; Antibodies ; Antibodies, Bacterial - blood ; Antibodies, Bacterial - immunology ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; antigens ; Booster ; Combination vaccines ; Data processing ; Diphtheria ; Diphtheria - immunology ; Diphtheria - prevention & control ; Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage ; Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects ; Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology ; Female ; Haemophilus Infections - immunology ; Haemophilus Infections - prevention & control ; Haemophilus Vaccines - administration & dosage ; Haemophilus Vaccines - adverse effects ; Haemophilus Vaccines - immunology ; Hepatitis B ; Hepatitis B - immunology ; Hepatitis B - prevention & control ; Humans ; Immune response ; Immunogenicity ; Infant ; Infants ; Male ; Pertussis ; Polio ; Poliomyelitis - immunology ; Poliomyelitis - prevention & control ; Poliovirus ; Poliovirus Vaccine, Inactivated - administration & dosage ; Poliovirus Vaccine, Inactivated - adverse effects ; Poliovirus Vaccine, Inactivated - immunology ; seroprevalence ; Tetanus ; Tetanus - immunology ; Tetanus - prevention & control ; Time Factors ; Vaccination ; Vaccine ; Vaccines ; Vaccines, Combined - administration & dosage ; Vaccines, Combined - adverse effects ; Vaccines, Combined - immunology]]></subject><ispartof>Vaccine, 2012-04, Vol.30 (17), p.2710-2714</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-b8ab65724b802cbf90d158be7c31f92c5f31a6e6c15ab891c5814847f21719bf3</citedby><cites>FETCH-LOGICAL-c476t-b8ab65724b802cbf90d158be7c31f92c5f31a6e6c15ab891c5814847f21719bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X12001958$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22349525$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Der Meeren, Olivier</creatorcontrib><creatorcontrib>Kuriyakose, Sherine</creatorcontrib><creatorcontrib>Kolhe, Devayani</creatorcontrib><creatorcontrib>Hardt, Karin</creatorcontrib><title>Immunogenicity of Infanrix ™ hexa administered at 3, 5 and 11 months of age</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>A pooled analysis of data from four vaccination studies conducted in Europe was undertaken to assess the immunogenicity of Infanrix™ hexa (DTPa–HBV–IPV/Hib, GlaxoSmithKline Biologicals) when administered in a total of 702 healthy infants at 3, 5 and 11–12 months of age. One month after dose 2, between 96.3% and 100% of subjects had seroprotective antibodies against diphtheria, tetanus, hepatitis B and poliovirus types 1, 2 and 3; 91.7% against Hib and ≥99.0% were seropositive for each pertussis antigen. One month after the third dose, 98.9–100% of subjects were seroprotected/seropositive for all vaccine antigens. Geometric mean antibody concentrations/titres for each vaccine antigen increased by 6.7–52.9 fold after the third vaccine dose. No serious adverse events in DTPa–HBV–IPV/Hib recipients were vaccine related. Infanrix™ hexa induces an adequate immune response after 2-dose primary plus booster doses when administered according to a 3, 5 and 11 months schedule.</description><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Antibodies</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antibodies, Bacterial - immunology</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>antigens</subject><subject>Booster</subject><subject>Combination vaccines</subject><subject>Data processing</subject><subject>Diphtheria</subject><subject>Diphtheria - immunology</subject><subject>Diphtheria - prevention & control</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology</subject><subject>Female</subject><subject>Haemophilus Infections - immunology</subject><subject>Haemophilus Infections - prevention & control</subject><subject>Haemophilus Vaccines - administration & dosage</subject><subject>Haemophilus Vaccines - adverse effects</subject><subject>Haemophilus Vaccines - immunology</subject><subject>Hepatitis B</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B - prevention & control</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunogenicity</subject><subject>Infant</subject><subject>Infants</subject><subject>Male</subject><subject>Pertussis</subject><subject>Polio</subject><subject>Poliomyelitis - immunology</subject><subject>Poliomyelitis - prevention & control</subject><subject>Poliovirus</subject><subject>Poliovirus Vaccine, Inactivated - administration & dosage</subject><subject>Poliovirus Vaccine, Inactivated - adverse effects</subject><subject>Poliovirus Vaccine, Inactivated - immunology</subject><subject>seroprevalence</subject><subject>Tetanus</subject><subject>Tetanus - immunology</subject><subject>Tetanus - prevention & control</subject><subject>Time Factors</subject><subject>Vaccination</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, Combined - administration & dosage</subject><subject>Vaccines, Combined - adverse effects</subject><subject>Vaccines, Combined - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkstuFDEQRS0EIkPgEwDvYEEPLj_6sQGhiMdIQSxCJHaW212eeOh2B7s7yuz5Ej6NL8GtGViwAKmk2px7q3SrCHkMbA0Mype79Y2x1gdccwZ8zZaSd8gK6koUXEF9l6wYL2UhgX05IQ9S2jHGlIDmPjnhXMhGcbUiHzfDMIdxi8FbP-3p6OgmOBOiv6U_v_-gV3hrqOkGH3yaMGJHzUTFC6qoCR0FoMMYpqu06MwWH5J7zvQJHx37Kbl89_bz2Yfi_NP7zdmb88LKqpyKtjZtqSou25px27qGdaDqFisrwDXcKifAlFhaUKatG7CqBlnLynGooGmdOCXPDr7Xcfw2Y5r04JPFvjcBxznpRmYVh5Jl8vk_yZxlBoWqVEbVAbVxTCmi09fRDybuM7Rwpd7pY-Z6yVyzpWTWPTmOmNsBuz-q3yFn4OkBcGbUZht90pcX2UExBpI3TGTi9YHAHNqNx6iT9Rgsdj6inXQ3-v8u8eovB9vnm1nTf8U9pt04x5AvokGnLNAXy2ssnwE8L9GoWvwCWx6xKg</recordid><startdate>20120405</startdate><enddate>20120405</enddate><creator>Van Der Meeren, Olivier</creator><creator>Kuriyakose, Sherine</creator><creator>Kolhe, Devayani</creator><creator>Hardt, Karin</creator><general>Elsevier Ltd</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20120405</creationdate><title>Immunogenicity of Infanrix ™ hexa administered at 3, 5 and 11 months of age</title><author>Van Der Meeren, Olivier ; Kuriyakose, Sherine ; Kolhe, Devayani ; Hardt, Karin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-b8ab65724b802cbf90d158be7c31f92c5f31a6e6c15ab891c5814847f21719bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Antibodies</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antibodies, Bacterial - immunology</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>antigens</topic><topic>Booster</topic><topic>Combination vaccines</topic><topic>Data processing</topic><topic>Diphtheria</topic><topic>Diphtheria - immunology</topic><topic>Diphtheria - prevention & control</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology</topic><topic>Female</topic><topic>Haemophilus Infections - immunology</topic><topic>Haemophilus Infections - prevention & control</topic><topic>Haemophilus Vaccines - administration & dosage</topic><topic>Haemophilus Vaccines - adverse effects</topic><topic>Haemophilus Vaccines - immunology</topic><topic>Hepatitis B</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B - prevention & control</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunogenicity</topic><topic>Infant</topic><topic>Infants</topic><topic>Male</topic><topic>Pertussis</topic><topic>Polio</topic><topic>Poliomyelitis - immunology</topic><topic>Poliomyelitis - prevention & control</topic><topic>Poliovirus</topic><topic>Poliovirus Vaccine, Inactivated - administration & dosage</topic><topic>Poliovirus Vaccine, Inactivated - adverse effects</topic><topic>Poliovirus Vaccine, Inactivated - immunology</topic><topic>seroprevalence</topic><topic>Tetanus</topic><topic>Tetanus - immunology</topic><topic>Tetanus - prevention & control</topic><topic>Time Factors</topic><topic>Vaccination</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, Combined - administration & dosage</topic><topic>Vaccines, Combined - adverse effects</topic><topic>Vaccines, Combined - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Der Meeren, Olivier</creatorcontrib><creatorcontrib>Kuriyakose, Sherine</creatorcontrib><creatorcontrib>Kolhe, Devayani</creatorcontrib><creatorcontrib>Hardt, Karin</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Der Meeren, Olivier</au><au>Kuriyakose, Sherine</au><au>Kolhe, Devayani</au><au>Hardt, Karin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of Infanrix ™ hexa administered at 3, 5 and 11 months of age</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2012-04-05</date><risdate>2012</risdate><volume>30</volume><issue>17</issue><spage>2710</spage><epage>2714</epage><pages>2710-2714</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>A pooled analysis of data from four vaccination studies conducted in Europe was undertaken to assess the immunogenicity of Infanrix™ hexa (DTPa–HBV–IPV/Hib, GlaxoSmithKline Biologicals) when administered in a total of 702 healthy infants at 3, 5 and 11–12 months of age. One month after dose 2, between 96.3% and 100% of subjects had seroprotective antibodies against diphtheria, tetanus, hepatitis B and poliovirus types 1, 2 and 3; 91.7% against Hib and ≥99.0% were seropositive for each pertussis antigen. One month after the third dose, 98.9–100% of subjects were seroprotected/seropositive for all vaccine antigens. Geometric mean antibody concentrations/titres for each vaccine antigen increased by 6.7–52.9 fold after the third vaccine dose. No serious adverse events in DTPa–HBV–IPV/Hib recipients were vaccine related. Infanrix™ hexa induces an adequate immune response after 2-dose primary plus booster doses when administered according to a 3, 5 and 11 months schedule.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>22349525</pmid><doi>10.1016/j.vaccine.2012.02.024</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2012-04, Vol.30 (17), p.2710-2714 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_948912160 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Age Allergy and Immunology Antibodies Antibodies, Bacterial - blood Antibodies, Bacterial - immunology Antibodies, Viral - blood Antibodies, Viral - immunology antigens Booster Combination vaccines Data processing Diphtheria Diphtheria - immunology Diphtheria - prevention & control Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology Female Haemophilus Infections - immunology Haemophilus Infections - prevention & control Haemophilus Vaccines - administration & dosage Haemophilus Vaccines - adverse effects Haemophilus Vaccines - immunology Hepatitis B Hepatitis B - immunology Hepatitis B - prevention & control Humans Immune response Immunogenicity Infant Infants Male Pertussis Polio Poliomyelitis - immunology Poliomyelitis - prevention & control Poliovirus Poliovirus Vaccine, Inactivated - administration & dosage Poliovirus Vaccine, Inactivated - adverse effects Poliovirus Vaccine, Inactivated - immunology seroprevalence Tetanus Tetanus - immunology Tetanus - prevention & control Time Factors Vaccination Vaccine Vaccines Vaccines, Combined - administration & dosage Vaccines, Combined - adverse effects Vaccines, Combined - immunology |
| title | Immunogenicity of Infanrix ™ hexa administered at 3, 5 and 11 months of age |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A58%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20Infanrix%20%E2%84%A2%20hexa%20administered%20at%203,%205%20and%2011%20months%20of%20age&rft.jtitle=Vaccine&rft.au=Van%20Der%20Meeren,%20Olivier&rft.date=2012-04-05&rft.volume=30&rft.issue=17&rft.spage=2710&rft.epage=2714&rft.pages=2710-2714&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2012.02.024&rft_dat=%3Cproquest_cross%3E948912160%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1011213575&rft_id=info:pmid/22349525&rft_els_id=1_s2_0_S0264410X12001958&rfr_iscdi=true |